Metformin Oresund Pharma (Metformin Hydrochloride)

Metformin works by inhibiting gluconeogenesis in the liver, which decreases the amount of glucose released into the bloodstream. It also activates AMP‑activated protein kinase (AMPK) in muscle and adipose tissue, enhancing glucose uptake and utilization, and modestly reduces intestinal glucose absorption. These combined actions improve overall insulin sensitivity and lower blood sugar levels.

The dosage of Metformin Oresund Pharma is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate starting dose, titration schedule, and maximum daily amount, ensuring safe and effective glycaemic management.

Metformin crosses the placenta and is excreted in breast milk; therefore, its safety in pregnancy and lactation must be evaluated by a qualified clinician. It may be prescribed during pregnancy only when the potential benefit outweighs potential risks, and breastfeeding mothers should discuss continuation with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any required temperature controls—and assists with import documentation.

Compared with sulfonylureas, Metformin does not stimulate insulin secretion, reducing the risk of hypoglycaemia. Unlike insulin therapy, it is administered orally and does not cause weight gain. Its cardiovascular safety profile is favourable, and it is often used as first‑line therapy for type 2 diabetes, whereas other classes may be added when glycaemic targets are not met.

Metformin Oresund Pharma should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments. Do not use the medication after the expiry date printed on the label.

Metformin Oresund Pharma is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets are swallowed whole with a sufficient amount of water and should not be crushed or chewed unless specifically directed by a healthcare professional. Dosing frequency and timing are determined by the prescriber based on individual therapeutic goals.

The most serious adverse risk of Metformin is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or in conjunction with certain contraindicated drugs. Prompt medical attention is required if symptoms such as unexplained fatigue, muscle pain, rapid breathing, or abdominal discomfort develop while on therapy.

Metformin Oresund Pharma is contraindicated in individuals with known hypersensitivity to metformin or other biguanides, those with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and patients receiving radiographic contrast studies without adequate renal monitoring. Clinicians should also exercise caution in patients with liver disease or heart failure.